Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 5/20 | 0.40 |
| ▸ | MAOA | P21397 | 3/20 | 0.40 |
| ▸ | ALPL | P05186 | 4/20 | 0.40 |
| ▸ | ALPI | P09923 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.37 |
| ▸ | PDE1A | P54750 | 1/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.36 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.36 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5618148 | 0.89 | ALPL (0.45) | CA1CA2MAOBMAOAALPL | |
| SCHEMBL5618472 | 0.88 | CA1 (0.39) | CA1CA2TP53MAPTRXFP1 | |
| SCHEMBL5618531 | 0.88 | USP2 (0.41) | CA1CA2MAOBMAOAALPL | |
| SCHEMBL5618116 | 0.86 | TUBB4A (0.42) | MAOBMAOAALPLALPIMAPT | |
| SCHEMBL5619070 | 0.86 | MAOB (0.36) | MAOBMAOAALPLALPIMAPT | |
| SCHEMBL4425544 | 0.77 | KDM4E (0.36) | MAOBMAOAMAPTRXFP1PABPC1 | |
| SCHEMBL5618825 | 0.76 | LMNA (0.37) | CA1CA2MAOBMAOAMAPT | |
| SCHEMBL4428460 | 0.76 | USP2 (0.37) | MAPT | |
| SCHEMBL4553664 | 0.74 | TUBB4A (0.42) | MAPTPABPC1 | |
| SCHEMBL5617892 | 0.71 | ALPL (0.53) | CA1CA2MAOBMAOAALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235674-B2 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-06-26 | — | — | US | claimed |
| US-20050090526-A1 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2005-04-28 | — | — | US | claimed |
| US-20030114485-A1 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-06-19 | — | — | US | claimed |
| US-7235674-B2 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7015328-B2 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-03-21 | — | — | US | disclosed |
| US-20050090526-A1 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2005-04-28 | — | — | US | disclosed |
| EP-1392283-A4 | SUBSTITUTED COUMARINS AND QUINOLINES AS CASPASE ACTIVATORS | CYTOVIA INC (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1392283-A1 | SUBSTITUTED COUMARINS AND QUINOLINES AS CASPASES ACTIVATORS | Cytovia, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030114485-A1 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-06-19 | — | — | US | disclosed |
| WO-2002092076-A1 | SUBSTITUTED COUMARINS AND QUINOLINES AS CASPASES ACTIVATORS | CYTOVIA, INC. (US) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114485-A1 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP7, CASP1, CASP5 | CA1 1998/4885CA2 1554/4885MAOB 1822/4885 |
| US-20050090526-A1 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP7, CASP5, CASP14 | CA1 2375/4885CA2 1646/4885MAOB 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.